Daphne Quimi's Insider Trades & SAST Disclosures
Daphne Quimi's most recent trade in Century Therapeutics Inc was a trade of 5,000 Common Stock done at an average price of $1.5 . Disclosure was reported to the exchange on Sept. 12, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Daphne Quimi.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Century Therapeutics Inc | Daphne Quimi | Director | Purchase of securities on an exchange or from another person at price $ 1.53 per share. | 12 Sep 2024 | 5,000 | 5,000 | - | 1.5 | 7,657 | Common Stock |
| Century Therapeutics Inc | Daphne Quimi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 44,000 | 44,000 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | Daphne Quimi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | Daphne Quimi | Director | Purchase of securities on an exchange or from another person at price $ 1.89 per share. | 14 May 2024 | 2,750 | 2,750 | - | 1.9 | 5,184 | Common Stock |
| Amylyx Pharmaceuticals Inc | Daphne Quimi | Director | Purchase of securities on an exchange or from another person at price $ 1.89 per share. | 14 May 2024 | 2,250 | 5,000 | - | 1.9 | 4,252 | Common Stock |
| Century Therapeutics Inc | Daphne Quimi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2023 | 44,000 | 44,000 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | Daphne Quimi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 16,985 | 16,985 | - | - | Stock Option (right to buy) | |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.00 per share. | 17 Jan 2023 | 6,923 | 398,532 (0%) | 0% | 13 | 89,999 | Common Stock |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.49 per share. | 17 Jan 2023 | 5,000 | 405,455 (0%) | 0% | 12.5 | 62,445 | Common Stock |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2023 | 58,824 | 440,020 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.02 per share. | 11 Jan 2023 | 29,565 | 410,455 (0%) | 0% | 12.0 | 355,371 | Common Stock |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.03 per share. | 04 Jan 2023 | 3,884 | 381,196 (0%) | 0% | 12.0 | 46,725 | Common Stock |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2023 | 130,480 | 130,480 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2023 | 73,508 | 393,655 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.21 per share. | 02 Jan 2023 | 15,165 | 320,147 (0%) | 0% | 12.2 | 185,165 | Common Stock |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.93 per share. | 02 Jan 2023 | 8,575 | 385,080 (0%) | 0% | 11.9 | 102,300 | Common Stock |
| Century Therapeutics Inc | Daphne Quimi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2022 | 39,744 | 39,744 | - | - | Stock Option (right to buy) | |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 11.29 per share. | 01 Sep 2022 | 4,397 | 335,312 (0%) | 0% | 11.3 | 49,621 | Common Stock |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 05 Aug 2022 | 5,798 | 339,709 (0%) | 0% | 12 | 69,576 | Common Stock |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 9.00 per share. | 17 Jun 2022 | 4,396 | 345,507 (0%) | 0% | 9 | 39,564 | Common Stock |
| Amylyx Pharmaceuticals Inc | Daphne Quimi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 19,000 | 19,000 | - | - | Stock Option (Right to Buy) | |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 36,840 | 368,746 (0%) | 0% | - | Common Stock | |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.53 per share. | 14 Jan 2022 | 18,843 | 349,903 (0%) | 0% | 10.5 | 198,417 | Common Stock |
| Amylyx Pharmaceuticals Inc | Daphne Quimi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 8,400 | 8,400 | - | - | Stock Option (Right to Buy) | |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Apr 2021 | 19,295 | 290,629 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2021 | 16,628 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 05 Mar 2021 | 16,628 | 275,998 (0%) | 0% | 2.9 | 48,886 | Common Stock |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.48 per share. | 05 Mar 2021 | 4,664 | 271,334 (0%) | 0% | 10.5 | 48,879 | Common Stock |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 9,502 | 264,140 (0%) | 0% | - | Common Stock | |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.84 per share. | 15 Jan 2021 | 4,770 | 259,370 (0%) | 0% | 21.8 | 104,153 | Common Stock |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 21 Dec 2020 | 5,000 | 249,344 (0%) | 0% | 2.9 | 14,700 | Common Stock |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2020 | 5,000 | 16,628 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 24.09 per share. | 21 Dec 2020 | 5,000 | 244,344 (0%) | 0% | 24.1 | 120,474 | Common Stock |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 11,500 | 21,628 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 15 Dec 2020 | 11,500 | 229,679 (0%) | 0% | 2.9 | 33,810 | Common Stock |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.38 per share. | 15 Dec 2020 | 7,550 | 237,229 (0%) | 0% | 4.4 | 33,069 | Common Stock |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 7,550 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 6,892 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.45 per share. | 15 Dec 2020 | 6,892 | 248,500 (0%) | 0% | 2.4 | 16,885 | Common Stock |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 4,379 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.53 per share. | 15 Dec 2020 | 4,379 | 241,608 (0%) | 0% | 3.5 | 15,458 | Common Stock |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.86 per share. | 15 Dec 2020 | 4,156 | 244,344 (0%) | 0% | 23.9 | 99,162 | Common Stock |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2020 | 11,000 | 6,892 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.45 per share. | 01 Oct 2020 | 11,000 | 218,179 (0%) | 0% | 2.5 | 26,950 | Common Stock |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.02 per share. | 01 Oct 2020 | 5,000 | 207,179 (0%) | 0% | 14.0 | 70,099 | Common Stock |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2020 | 5,000 | 33,128 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 01 Oct 2020 | 5,000 | 212,179 (0%) | 0% | 2.9 | 14,700 | Common Stock |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2020 | 13,000 | 17,892 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.45 per share. | 01 Jul 2020 | 13,000 | 207,179 (0%) | 0% | 2.5 | 31,850 | Common Stock |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 01 Jul 2020 | 6,872 | 214,051 (0%) | 0% | 2.9 | 20,204 | Common Stock |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2020 | 6,872 | 28,128 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 15.47 per share. | 01 Jul 2020 | 6,872 | 207,179 (0%) | 0% | 15.5 | 106,326 | Common Stock |
| Amicus Therapeutics Inc | Daphne Quimi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.14 per share. | 15 Jun 2020 | 1,046 | 194,179 (0%) | 0% | 11.1 | 11,652 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges